FUTURE ONCOL 润色咨询

Future Oncology

出版年份:2005 年文章数:2434 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:6.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2024-02-29 重复的用户名 来自浙江省

    投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-02-02 ms6000000603665223 来自湖南省

    这个杂志接受综述吗

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2022-12-30 ms2000000288456127 来自河南省

    兄弟们,这个期刊要不要综述啊,不是约稿的那种

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-01-02 125366dam34暂无昵称

    审稿速度:24.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤;放疗;基础研究
    经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-04-17 ms7000000764732971 来自北京

    请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-04-27 ms6000000107141238 来自上海

    有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-04-17 ms7000000764732971 来自北京

    1-26投出 至今还在审

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2023-04-17 ms7000000764732971 来自北京

    请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2021-11-26 水逆退散~

    偏重的研究方向:肿瘤
    经验分享:11.04投稿,11.24under consideration

    7

    展开7条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月,状态从In Peer Review 改为Under Consideration,请问这是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们,这个期刊要不要综述啊,不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;放疗;基础研究<br>经验分享:期刊非常非常慢,去年10月投稿,今年12月接收,期间一直在under review,审稿人和编辑一起提了30多个问题,response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀?我是1-26提交的,目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗?有资源的帮帮我?电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2126416, encodeId=d1d8212641699, content=1-26投出 至今还在审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:14:38 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊,我1-26提交的仍然是in peer review,快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1074255, encodeId=73f110e42556f, content=偏重的研究方向:肿瘤<br>经验分享:11.04投稿,11.24under consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散~, createdTime=Fri Nov 26 15:27:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897146, encodeId=bc4189e14644, content=9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Thu Nov 05 16:20:33 CST 2020, time=2020-11-05, status=1, ipAttribution=)]
    2020-11-05 122220a4m01暂无昵称

    9-24投稿 10-21小修 10-26修回 11-5接收 编辑态度很好,速度很快,以后有合适的稿件还会再投。

    7

    展开7条回复
共165条页码: 1/17页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分